- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07491172
En sikkerheds- og tolerabilitetsundersøgelse, der evaluerer CTX310 hos deltagere med refraktære dyslipidemier
En fase 1, åben, multicentrisk, første-på-mennesker, stigende dosisundersøgelse, der evaluerer sikkerheden og tolerabiliteten af en lipidnanopartikelformulering af CRISPR-guide RNA-Cas9 nuclease (CTX310) til in vivo-redigering af angiopoietin-lignende 3 (ANGPTL3)-genet hos deltagere med refraktære dyslipidemier
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a phase 1, open-label, multi-center study of CTX310 in participants with refractory dyslipidemias. Subjects will receive a dose of CTX310 via intravenous (IV) infusion.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Clinical Trials
- Telefonnummer: 877-214-4634
- E-mail: medicalaffairs@crisprtx.com
Studiesteder
-
-
-
Adelaide, Australien, 5000
- Rekruttering
- Royal Adelaide
-
Kontakt:
- Denise Healy
- Telefonnummer: +61 409 877 807
- E-mail: Denise.Healy@sa.gov.au
-
Brisbane, Australien, 4064
- Rekruttering
- CORE Research
-
Kontakt:
- Daunte Tamaki
- Telefonnummer: 07 + 38765688
- E-mail: daunte.tamaki@coreresearchgroup.com
-
Camperdown, Australien, 2050
- Ikke rekrutterer endnu
- Royal Prince Alfred Hospital
-
Kontakt:
- Aimei Lee
- Telefonnummer: (02) + 9515 4860
- E-mail: aimei.lee@health.nsw.gov.au
-
Heidelberg, Australien, 3084
- Rekruttering
- Austin Health
-
Kontakt:
- Adele Manzoney
- Telefonnummer: +613 9496 2160
- E-mail: adele.manzoney@unimelb.edu.au
-
Melbourne, Australien, 3168
- Rekruttering
- Monash Medical Center
-
Kontakt:
- Debra O'Leary
- Telefonnummer: +61 3 75111243
- E-mail: debra.oleary@monashhealth.org
-
-
-
-
-
Cambridge, Det Forenede Kongerige
- Rekruttering
- Royal Papworth Hospital
-
Kontakt:
- Jenny Castedo
- Telefonnummer: +441223 638000
- E-mail: jenny.castedo1@nhs.net
-
London, Det Forenede Kongerige, SE1 1YR
- Rekruttering
- Richmond Pharmacology
-
Kontakt:
- Volunteer Recruitment Team
- Telefonnummer: +44 (0)20 7042 5800
- E-mail: volunteer@richmondpharmacology.com
-
-
-
-
Florida
-
Hialeah, Florida, Forenede Stater, 33015
- Rekruttering
- Integrity Clinical Research
-
Kontakt:
- Celia Padron
- Telefonnummer: 786-953-6263
- E-mail: cpadronmd@integrityresearchcenter.com
-
Jacksonville, Florida, Forenede Stater, 32216
- Rekruttering
- Jacksonville Center for Clinical Research
-
Kontakt:
- Sonia Gerardo
- Telefonnummer: 904-730-0101
-
Orlando, Florida, Forenede Stater, 32789
- Rekruttering
- Flourish Orlando
-
Kontakt:
- Stephanie Munoz
- Telefonnummer: 407-740-8078
- E-mail: smunoz@flourishresearch.com
-
Port Orange, Florida, Forenede Stater, 32127
- Rekruttering
- United Medical Research
-
Kontakt:
- Bhanu Visalingam
- Telefonnummer: 386-523-9498
- E-mail: drvisvalingam@progressivemedicalresearch.com
-
-
New York
-
Rochester, New York, Forenede Stater, 14642
- Rekruttering
- University of Rochester
-
Kontakt:
- Jeffrey Bruckel
- Telefonnummer: 585-275-2475
- E-mail: Jeffrey_Bruckel@URMC.Rochester.edu
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27710
- Rekruttering
- Duke Early Phase Clinical Research
-
Kontakt:
- Debbie Freeman
- Telefonnummer: 919-613-1223
- E-mail: debra.h.freeman@duke.edu
-
High Point, North Carolina, Forenede Stater, 27260
- Rekruttering
- Peters Medical Research
-
Kontakt:
- Erika Jordan
- Telefonnummer: 336-883-9773
- E-mail: erikaj@petersmedicalresearch.com
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- Rekruttering
- Oregon Health & Science University (OHSU)
-
Kontakt:
- Hailey Volk
- Telefonnummer: 503-494-2004
- E-mail: volkh@ohsu.edu
-
-
-
-
-
Auckland, New Zealand, 2025
- Rekruttering
- Aotearoa
-
Kontakt:
- Kate Msiska
- Telefonnummer: +64 (0) 21 850 235
- E-mail: kate.msiska@aotearoatrials.nz
-
Christchurch, New Zealand, 8011
- Rekruttering
- NZCR
-
Kontakt:
- Jo Sanders
- Telefonnummer: +64 (0) 3 372 9477
- E-mail: jo.sanders@nzcr.co.nz
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Age of ≥18 and ≤75 years at the time of signing the informed consent.
- Able to provide written informed consent.
- Participants diagnosed with persistent dyslipidemias defined by TG ≥150 mg/dL - and LDL-C ≥70 mg/dL in participants with ASCVD, or LDL-C ≥70 or 100mg/dL in participants with or without ASCVD respectively, or TG ≥500 mg/dL.
- Refractory to the maximal intensity or MTD of standard of care lines of lipid-lowering therapies available through routine clinical care, for at least 12 weeks prior to screening
- Female participants must be postmenopausal or surgically sterile.
- All male participants and their female partners must agree to the use of an acceptable method of effective contraception for the duration of the study.
Exclusion Criteria:
-
Participants with familial chylomicronemia syndrome (FCS). Some exceptions may apply.
-
Evidence of liver disease, defined as but not limited to:
LFTS >2 × upper limit of normal (ULN), or total bilirubin >2 × ULN, or INR >1.5 × ULN, or liver stiffness measured by liver elastography
-
Abnormal or compromised function of kidney, heart, blood or liver.
-
Acute coronary syndrome event or stroke within 24 weeks prior to Day 1. Acute pancreatitis within 12 weeks prior to Day 1.
-
Current use or use within 365 days from Day 1 of any hepatocyte-targeted small interfering RNA (except inclisiran).
-
Positive serology for HIV, hepatitis B or hepatitis C (antibody, surface antigen orNAT). Serology consistent with prior immunization will be eligible for the trial.
-
Any prior malignancy within the past 5 years, or current malignancy (exceptions for resected or removed basal cell carcinoma, squamous cell carcinoma in situ and carcinoma in situ of the cervix or breast).
-
Women of childbearing potential.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Note: The inclusion and exclusion criteria listed represent the global protocol. Additional or modified eligibility criteria may apply in certain countries in accordance with local regulatory and ethics committee requirements and the approved country-specific protocol.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: CTX310
Subjects will receive an intravenous (IV) infusion. |
CTX310 is a lipid nanoparticle (LNP) formulation of clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) components for in vivo editing of the target gene angiopoietin-like 3 (ANGPTL3). |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
To evaluate the safety of CTX310 in adult subjects with dyslipidemias that are refractory to available treatments
Tidsramme: From CTX310 infusion up to 12 months
|
Incidence of dose-limiting toxicities and frequency of adverse events |
From CTX310 infusion up to 12 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
To assess the preliminary efficacy of CTX310 in adult participants with dyslipidemias that are refractory to available treatments
Tidsramme: Over 12 months, compared to baseline
|
Percentage change from baseline in lipid values (LDL-C, non-HDL-C, Trigs, apoB and HDL-C) |
Over 12 months, compared to baseline
|
|
To further characterize the safety of CTX310 in adult participants with dyslipidemias that are refractory to available treatments
Tidsramme: From CTX310 infusion up to 12 months
|
Frequency and severity of adverse events (AE), including treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESIs), clinically significant laboratory abnormalities, and clinically significant abnormal vital signs. |
From CTX310 infusion up to 12 months
|
|
To assess the pharmacokinetics (PK) of CTX310 in adult participants with dyslipidemias that are refractory to available treatments
Tidsramme: From CTX310 infusion up to 12 months
|
Levels of CTX310 in blood over time |
From CTX310 infusion up to 12 months
|
|
To assess the pharmacodynamic (PD) response of CTX310 in adult participants with dyslipidemias that are refractory to available treatments
Tidsramme: Over 12 months, compared to baseline
|
Percentage change from baseline of ANGPTL3 |
Over 12 months, compared to baseline
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Metabolisme, medfødte fejl
- Genetiske sygdomme, medfødte
- Hyperlipidæmi
- Lipidmetabolisme, medfødte fejl
- Hyperlipoproteinæmier
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Ernæringsmæssige og metaboliske sygdomme
- Hyperlipoproteinæmi Type II
- Homozygot familiær hyperkolesterolæmi
- Hyperkolesterolæmi
- Dyslipidæmi
- Metaboliske sygdomme
- Hypertriglyceridæmi
- Lipidmetabolismeforstyrrelser
- Hyperlipoproteinæmi Type V
Andre undersøgelses-id-numre
- CRSP-CVD-400
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .